Drug Search Results
More Filters [+]

INBRX-130

Alternative Names: INBRX-130, INBRX130, INBRX 130
Latest Update: 2022-03-24
Latest Update Note: News Article

Product Description

INBRX-130 is a CONTRA-MAB® that targets trophoblast glycoprotein (TPBG; 5T4), a cell-surface protein that is upregulated across many solid tumor indications but has restricted expression on normal adult tissues. As determined by flow cytometry, INBRX-130 exhibits specific and high-affinity binding to 5T4-positive cells but shows no detectable binding to T cells, absent target, at concentrations up to one micromolar. Additionally, treatment of peripheral blood mononuclear cells (PBMCs) with high concentration INBRX-130 does not result in production of detectable levels of CRS-associated inflammatory cytokines. (Sourced from: https://aacrjournals.org/cancerres/article/82/12_Supplement/2912/700371/Abstract-2912-INBRX-130-a-5T4-targeted-CONTRA-MAB)

Mechanisms of Action: TPBG Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Inhibrx
Company Location: LA JOLLA CA 92037
Company CEO: Mark P. Lappe
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for INBRX-130

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events